Merck & Co (NY:MRK)

In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.

Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declines ↗

November 03, 2026

Via Chartmill

Topics Stocks

3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively ↗

November 03, 2026

Merck & Co. (NYSE:MRK) Posts Q3 Earnings Beat as EPS Surprise Offsets In-Line Sales Guidance ↗

Topics Economy

Dow Jones Biggest Decliners in Today's US Session ↗

November 03, 2026

Via Chartmill

Topics Stocks

October 29, 2026

Via Chartmill

Topics Earnings

Tempus AI Surges on Earnings Beat, But Can the Rally Last? ↗

November 03, 2026

Tempus AI posted Q3 revenue up 23.1% and a surprise profit, raised guidance, and saw shares surge 10%, though analysts cite cash burn and limited 2026 upside.

Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

Topics Artificial Intelligence Earnings Initial Public Offering

November 03, 2026

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗

November 02, 2026

Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

November 02, 2026

Investors were still buying it in the afterglow of its latest quarterly earnings release.

Why Merck Stock Flew Higher on Friday ↗

October 30, 2026

Global pharmaceutical company Merck (NYSE:MRK) reported revenue ahead of Wall Street’s expectations in Q3 2026, with sales up 4.7% year on year to $18.09 bil...

Topics Intellectual Property

MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds

October 30, 2026

Via StockStory

Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop

October 30, 2026

From Glancy Prongay Wolke & Rotter LLP

Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline

October 30, 2026

From The Law Offices of Howard G. Smith

Merck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset...

Merck & Co., Inc. Q3 Earnings Call Highlights ↗

October 30, 2026

Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline

Topics Earnings

October 29, 2026

From The Law Offices of Frank R. Cruz

Dow Jones Top Movers for Oct. 29, 2026: Merck and Nike Lead Gainers, Alphabet and Caterpillar Fall ↗

October 29, 2026

Via Chartmill

Topics Stocks

Merck (MRK) Q3 2026 Earnings Call Transcript ↗

October 29, 2026

Generic headwinds ahead in 2027, but new launches and WINREVAIR growth signal momentum.

Merck’s new drugs are growing fast enough to cover generic losses, but part of this quarter’s sales gain won’t last. Here’s what to watch.

Topics Earnings

Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings Reaction ↗

October 29, 2026

Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q3 2026, with revenue rising 4.7% year on year to $18.09 billion. Th...

Topics Intellectual Property

Dow Jones Top Movers Today: 8 Gainers, 4 Losers in Split Session ↗

October 29, 2026

Via Chartmill

Topics Stocks

Merck (NYSE:MRK) delivers impressive Q3 2026

October 29, 2026

Via StockStory

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline

October 29, 2026

The path for Revolution Medicines to grow an initial investment of $25,000 into $1 million is a daunting one.

Could Revolution Medicines Be a Millionaire-Maker Stock? ↗

October 29, 2026

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday before market open. Here’s what investors should know. Merck beat ana...

Merck (MRK) reports Q3: everything you need to know ahead of earnings

October 27, 2026

Via StockStory

Topics Artificial Intelligence

Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? ↗

October 27, 2026

Merck and Moderna's melanoma vaccine cut recurrence risk 42% in a Phase 3 trial, but results fell short of hopes, sending Moderna shares down sharply while Merck stock barely moved.

Merck & Co., Inc. (NYSE:MRK) outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab...

Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts ↗

October 26, 2026

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

S&P 500 Top Movers: Gainers and Losers in Today's US Session ↗

October 26, 2026

Via Chartmill

Topics Stocks

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗

October 26, 2026

KEYTRUDA® (pembrolizumab) as Monotherapy Reduced the Risk of Disease Progression or Death by 43% for Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy

Topics Artificial Intelligence

October 26, 2026

Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer

October 26, 2026